Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTOL-1: Oral treprostinil for digital ischemic lesions in systemic sclerosis
2008-005018-39Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) and scleroderma comparing Treprostinil diethanolamine with Placebo (2 arms). Primary endpoint: Reduction in net ulcer burden. Started May 2009; status: completed.
02
Drugs
treprostinil
03
Conditions
systemic sclerosis (SSc)scleroderma
Beyond the preview
Go deeper on 2008-005018-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005018-39.